Sponsor link https://cdn.pfizer.com/pfizercom/2023-02/GMG-2023-ONC-US_Myovant-PfizerA...

Not for to support of clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Areas of interest:

Increasing awareness of disparities in care and barriers to treatment access for prostate cancer care, specifically LHRH agonists and GnRH receptor antagonists, with the goal of closing gaps in care and allowing equal access • Raising awareness of opportunities to improve the quality of ADT treatment across diverse patient populations • Evaluating patient preferences and adherence data regarding oral versus parenteral oncologic therapy for prostate cancer • Raising awareness of non-oncologic risks and comorbidities in patients with prostate cancer receiving ADT (e.g., cardiovascular, metabolic risk, bone health) • Understanding the efficacy and safety profiles of LHRH agonists and GnRH receptor antagonists